اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,846
تعداد مقالات32,300
تعداد مشاهده مقاله41,387,016
تعداد دریافت فایل اصل مقاله18,562,143
Ghazi Jumaa, M. (1400). Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer. سامانه مدیریت نشریات علمی, 77(1), 205-211. doi: 10.22092/ari.2021.356992.1956
M Ghazi Jumaa. "Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer". سامانه مدیریت نشریات علمی, 77, 1, 1400, 205-211. doi: 10.22092/ari.2021.356992.1956
Ghazi Jumaa, M. (1400). 'Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer', سامانه مدیریت نشریات علمی, 77(1), pp. 205-211. doi: 10.22092/ari.2021.356992.1956
Ghazi Jumaa, M. Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer. سامانه مدیریت نشریات علمی, 1400; 77(1): 205-211. doi: 10.22092/ari.2021.356992.1956

Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer

Archives of Razi Institute
مقاله 28، دوره 77، شماره 1، فروردین و اردیبهشت 2022، صفحه 205-211    اصل مقاله (548.15 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.356992.1956
نویسنده
M Ghazi Jumaa*
Department of Microbiology, College of Medicine, University of Maisan, Maisan, Iraq
چکیده
In carcinogenesis, KRAS is an essential oncogene that plays a key function. The polymorphism of rs61764370 is a candidate for cancer susceptibility in KRAS3' untranslated region. The current study aimed to determine the role and impact of the KRAS gene polymorphism (rs61764370 T>G) on the risk of ovarian cancer development in the Iraqi population. In total, 84 ovarian cancer patients and 28 ovarian benign tumors were involved in a case-control study. DNA extraction from the formalin-fixed/paraffin-embedded tissues, followed by the sequencing of PCR products was carried out in genetic analysis for the detection of the KRAS polymorphism (rs61764370 T>G). The results showed that the frequencies of the KRAS gene polymorphism (rs61764370) in ovarian cancer patients were 78 (92.85%) and 6 (7.15%) with genotypes homozygote TT and heterozygote TG, respectively. These corresponding values in patients with benign ovarian tumors were 25 (89.3%) and 3 (10.7%) with homozygote TT and heterozygote TG, respectively. None of the patients either with malignant or benign tumors have been detected with homozygote genotype GG. Genotype frequency of the TT and TG showed that the heterozygote TT genotype vs. TG and T allele vs. G allele were more frequent in malignant and benign tumors (P≤0.01). Statistically, there was no association between the KRAS polymorphism and the clinical characteristics of ovarian cancer patients, such as age, family history, menopause, histological type, tumor size, or tumor stage. In conclusion, a significant association was found between rs61764370 and the risk of ovarian cancer in the Iraqi population, particularly those with genotypes homozygote TT. On the other hand, genotypes had no relationship with any of the clinical characteristics of ovarian cancer patients. Additional well-designed studies with larger sample sizes are recommended to validate the precise role of KRAS LCS6 variations in ovarian cancer risk.
کلیدواژه‌ها
KRAS؛ LCS6 Polymorphism؛ Ovarian cancer؛ rs61764370 T>G
سایر فایل های مرتبط با مقاله
مراجع
  1. Ferlay J, Parkin D, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J cancer. 2010;46(4):765-81.
  2. Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev. 2010;20(3):231-8.
  3. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756(2):81-2.
  4. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010;70(16):6509-15.
  5. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non–small cell lung cancer risk. Cancer Res. 2008;68(20):8535-40.
  6. Nelson H, Christensen B, Plaza S, Wiencke J, Marsit C, Kelsey K. KRAS mutation, KRAS–LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer. 2010;69(1):51-3.
  1. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, et al. A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011;12(4):377-86.
  2. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 2012;31(42):4559-66.
  3. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res. 2011;17(11):3742-50.
  4. Wang H, Bhutta ZA, Coates MM, Coggeshall M, Dandona L, Diallo K, et al. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1725-74.
  5. Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M. KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res. 2012;2(3):298.
  6. D’Hooghe TM, Grechukhina O, Cho S, Fassbender A, Dorien O, Peterse D, et al. Lack of an Association between a Polymorphism in the KRAS 3′ Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. Gynecol Obstet Inves. 2019;84(6):575-82.
  7. Farahani MS, Shahbazi S, Moghaddam SA, Mahdian R. Evaluation of KRAS gene expression and LCS6 variant in genomic and cell-free DNA of Iranian women with endometriosis. Reprod Sci. 2015;22(6):679-84.
  8. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, et al. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PloS One. 2012;7(5):e37891.
  9. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol. 2011;223(2):220-30.
  10. Ganzinelli M, Rulli E, Caiola E, Garassino MC, Broggini M, Copreni E, et al. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep. 2015;5(1):1-8.
  1. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22(1):104-9.
  2. Al-Haddad R. Lack of Association between LCS6 Variant in KRAS Gene with the Occurrence of Breast Tumors in Iraqi Women. Baghdad Sci J. 2020;17(2):0426-.
  3. Farokhzad N, Hosseini SM, Edalat H, Sadeghi M. Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population. Afr Health Sci. 2020;20(3):1299-303.
  1. Sanaei S, Hashemi M, Eskandari E, Hashemi SM, Bahari G. KRAS gene polymorphisms and their impact on breast cancer risk in an iranian population. Asian Pac J Cancer Prev. 2017;18(5):1301.
  2. Mohthash M, Shah SK, Thirupathi A. KRAS gene polymorphism (rs61764370) and its impact on breast cancer risk among women in kerala population, South India. J Nat Sci Biol Med. 2020;11(2):140.
آمار
تعداد مشاهده مقاله: 1,231
تعداد دریافت فایل اصل مقاله: 337


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب